Diagnosing and treating the "flesh-eating bacteria syndrome"

Cleveland Clinic Journal of Medicine

Volumn 65, Issue 5, 1998, Pages 241-249

  File Jr , Thomas M ^a,b,c   Tan, James S ^a,b   Dipersio, Joseph R ^a,b  

^a SUMMA HEALTH SYSTEM   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c NE Ohio Universities Coll of Med ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CILASTATIN; CLAVULANIC ACID; CLINDAMYCIN; IMIPENEM; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN; TAZOBACTAM; TICARCILLIN;

ANTIBIOTIC THERAPY; CELLULITIS; DEBRIDEMENT; HUMAN; HYPERBARIC OXYGEN; INCIDENCE; MICROBIOLOGY; NECROTIZING FASCIITIS; PATIENT CARE; REVIEW; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME; DIFFERENTIAL DIAGNOSIS; PATHOGENICITY; SEPTIC SHOCK; TOXIC EPIDERMAL NECROLYSIS;

CELLULITIS; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; FASCIITIS, NECROTIZING; HUMANS; SHOCK, SEPTIC; STREPTOCOCCUS PYOGENES;

EID: 0032063563     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.5.241     Document Type: Review

References (40)

1. Swartz MN. Cellulitis and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R (editors). Principles and Practice of Infectious Diseases. Fourth ed. Philadelphia: W.B. Saunders, 1995:909-929.
2. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240-245.
3. Giuliano A, Lewis F, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis. Am J Surg 1977; 134:52-57.
4. Stevens DL. Invasive group A streptococcus infection. Clin Infect Dis 1992; 14:2-13.
5. Musser JM. Molecular population genetic analysis of emerged bacterial pathogens: selected insights. Emerging Infect Dis 1996(2):1-17.
6. Barnham M, Holm SE. Serious Streptococcus pyogenes disease. Clin Microbiol Infect 1997; 3:250-260.
7. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993; 269:390-391.
8. Loudon I. Necrotising fasciitis, hospital gangrene, and phagedena. Lancet 1994; 344:1416-1419.
9. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-7.
10. Hoge CW, Schwartz B, Talkington DF, Brieman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. JAMA 1993; 269:384-389.
11. Lancefield RC. Current knowledge of type specific M antigens of group A streptococci. J Immunol 1962; 89:307-313.
12. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990; 336:1167-1171.
13. Nakashima K, Ichiyama S, Iinuma Y, et al. A bacteriologic investigation of invasive streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints. Clin Infect Dis 1997; 25:260-266.
14. Kiska DL, Thiede B, Caracciolo J, et al. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis 1997; 176:992-1000.
15. Gamba MA, Martinelli M, Schaad HJ, et al. Familial transmission of a serious disease-producing group A streptococcus clone: case reports and review. Clin Infect Dis 1997; 24:1118-1121.
16. Cleary PP, Kapland EL, Handley JP, et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980's. Lancet 1992; 339:518-521.
17. Chaussee M, Liu J, Stevens DL, Ferrett JJ. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Infect Dis 1996; 173:901-908.
18. Mollick JA, Rich RR. Characterization of a superantigen from a pathogenic strain of Streptococcus pyogenes. Clin Res 1991; 14:2-11.
19. Stevens DL, Bryant AE, Hackett SP, et al. Group A streptococcal bacteremia: The role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996; 173:619-626.
20. DiPersio JR, File TMJ, Stevens DL, Gardner WG, Petropoulos G, Dinsa K. Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis 1996; 22:490-495.
21. DiPersio JR, Stevens DL, Beach JA, et al. Molecular analysis of invasive M3 group A Streptococcus clones from Akron and other geographic locations. Miami Beach, FL: American Society of Microbiology, 1997.
22. Stevens DL. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995; 21:977-980.
23. Kaul R, McGeer A, Low D, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 1997; 103:18-24.
24. Chelsom J, Halstensen A, Haga R, Hoiby EA. Necrotizing fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994; 344:1111-1115.
25. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 2:69-78.
26. McHenry CR, Piotrowski JJ, Petrinick D, Malangoni MA. Determinants for mortality for necrotizing soft tissue infections. Ann Surg 1995; 221:558-563.
27. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23-28.
28. Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952; 13:389-399.
29. Stevens DL, Van S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167:1401-1405.
30. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987; 31:213-218.
31. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981; 67:1249-1256.
32. Matthieu D, Neviere R, Teillon C, Chagnon JL, Lebleu N, Wattel F. Cervical necrotizing fasciitis: clinical manifestations and management. Clin Infect Dis 1995; 21:51-56.
33. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces morality and the need for debridements. Surgery 1990; 108:847-850.
34. Shupak A, Shoshani O, Goldenberg I, Barzilai A, Moskuna R, Bursztein A. Necrotizing fasciitis: an indication for hyperbaric oxygen therapy? Surgery 1995; 118:873-878.
35. Stegmayr B, Bjorck S, Holm SE, Nisell J, Rydvall A, Settergren B. Septic shock induced by group A streptococcal infections: clinical and therapeutic aspects. Scand J Infect Dis 1992; 24:589-597.
36. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992; 267:3315-3316.
37. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe group A streptococcal infections treated with normal polyspecific IgG inhibits streptococci; superantigen induced T cell proliferation and cytokine expression. J Immunol 1996; 156:3057-3064.
38. Yong JM. Necrotizing fasciitis. Lancet 1994; 343:1427-1428.
39. Holm SE, Norrby A, Bergholm A-M, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden. J Infect Dis 1992; 166:31-37.
40. Norgren M, Norrby A, Holm SE. Genetic diversity in T1M1 group A streptococci in relation to clinical outcome of infection. J Infect Dis 1992; 166:1014-1020.